ALX Oncology (NASDAQ:ALXO) Cut to “Sell” at Wall Street Zen

by · The Cerbat Gem

Wall Street Zen cut shares of ALX Oncology (NASDAQ:ALXO – Free Report) from a hold rating to a sell rating in a research report report published on Sunday morning.

A number of other equities analysts also recently weighed in on the stock. Jefferies Financial Group initiated coverage on shares of ALX Oncology in a report on Thursday, November 13th. They issued a “buy” rating and a $4.00 price target on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ALX Oncology in a research report on Wednesday, October 8th. Five equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, ALX Oncology presently has an average rating of “Moderate Buy” and a consensus target price of $3.50.

View Our Latest Analysis on ALX Oncology

ALX Oncology Stock Performance

ALXO stock opened at $1.43 on Friday. The company has a quick ratio of 2.40, a current ratio of 2.40 and a debt-to-equity ratio of 0.13. The firm has a market cap of $77.53 million, a PE ratio of -0.70 and a beta of 0.53. The business has a 50 day moving average of $1.50 and a 200-day moving average of $1.07. ALX Oncology has a 12-month low of $0.40 and a 12-month high of $2.27.

ALX Oncology (NASDAQ:ALXO – Get Free Report) last posted its quarterly earnings data on Friday, November 7th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.04). As a group, sell-side analysts expect that ALX Oncology will post -2.76 earnings per share for the current year.

Hedge Funds Weigh In On ALX Oncology

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Invesco Ltd. purchased a new position in shares of ALX Oncology in the first quarter worth about $46,000. Nuveen LLC bought a new position in ALX Oncology in the 1st quarter worth approximately $103,000. Almitas Capital LLC grew its stake in ALX Oncology by 10.6% in the 1st quarter. Almitas Capital LLC now owns 1,353,141 shares of the company’s stock valued at $843,000 after buying an additional 130,196 shares in the last quarter. AQR Capital Management LLC boosted its holdings in shares of ALX Oncology by 183.6% in the first quarter. AQR Capital Management LLC now owns 119,050 shares of the company’s stock worth $74,000 after acquiring an additional 77,065 shares during the period. Finally, Acadian Asset Management LLC grew its holdings in ALX Oncology by 16.8% during the 1st quarter. Acadian Asset Management LLC now owns 1,296,331 shares of the company’s stock valued at $806,000 after buying an additional 186,883 shares in the last quarter. Institutional investors own 97.97% of the company’s stock.

About ALX Oncology

(Get Free Report)

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.

Further Reading